John W. Kozarich Sells 2,500 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director John W. Kozarich sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $145.00, for a total value of $362,500.00. Following the transaction, the director now owns 33,149 shares of the company’s stock, valued at approximately $4,806,605. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ligand Pharmaceuticals Inc. (LGND) traded up $1.78 on Friday, reaching $147.95. The company had a trading volume of 177,800 shares, compared to its average volume of 220,300. The stock has a market capitalization of $3,140.00, a price-to-earnings ratio of 214.42, a P/E/G ratio of 1.51 and a beta of 0.91. Ligand Pharmaceuticals Inc. has a 12 month low of $95.08 and a 12 month high of $149.31. The company has a current ratio of 0.97, a quick ratio of 0.95 and a debt-to-equity ratio of 0.05.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.32. The company had revenue of $33.38 million during the quarter, compared to analyst estimates of $31.04 million. Ligand Pharmaceuticals had a return on equity of 7.83% and a net margin of 12.76%. The firm’s revenue was up 54.4% on a year-over-year basis. During the same quarter last year, the business posted $0.62 earnings per share. analysts predict that Ligand Pharmaceuticals Inc. will post 3.15 earnings per share for the current year.

LGND has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $157.00 price objective on shares of Ligand Pharmaceuticals in a research report on Thursday, October 5th. Deutsche Bank lowered Ligand Pharmaceuticals from a “hold” rating to a “sell” rating and set a $105.00 price objective for the company. in a research report on Monday, November 20th. Zacks Investment Research upgraded Ligand Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $165.00 price target for the company in a research report on Thursday, October 12th. Craig Hallum reiterated a “buy” rating and issued a $170.00 price target (up previously from $160.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, November 15th. Finally, Roth Capital reiterated a “buy” rating and issued a $158.00 price target (up previously from $135.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Ligand Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $150.67.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Harbor Advisors LLC purchased a new position in Ligand Pharmaceuticals in the third quarter worth about $204,000. Round Table Services LLC bought a new stake in Ligand Pharmaceuticals in the third quarter worth about $205,000. Riverhead Capital Management LLC lifted its stake in Ligand Pharmaceuticals by 99.8% in the second quarter. Riverhead Capital Management LLC now owns 1,798 shares of the biotechnology company’s stock worth $218,000 after purchasing an additional 898 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in Ligand Pharmaceuticals by 9.4% in the second quarter. Ameritas Investment Partners Inc. now owns 1,799 shares of the biotechnology company’s stock worth $218,000 after purchasing an additional 154 shares during the last quarter. Finally, Stephens Inc. AR lifted its stake in Ligand Pharmaceuticals by 13.0% in the second quarter. Stephens Inc. AR now owns 1,821 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 210 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: This report was posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2018/01/12/john-w-kozarich-sells-2500-shares-of-ligand-pharmaceuticals-inc-lgnd-stock.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit